ANVISA Updates COVID Vaccine and Low-Risk Medicines Classification
ANVISA updated the regulatory framework for COVID-19 vaccines and revised the classification of low-risk medicines, impacting regulatory requirements and product categorization.
ANVISA | Pharmaceuticals | Country Regulatory AffairsMobile?scanning & Digital?labeling Rules for Centrally Authorised Medicinal Products
EMA CMDh finalizes guidance on mobile scanning and other technologies in the labeling and package leaflet of centrally authorised medicinal products
EMA / CMDh | Pharmaceuticals | Regulatory LabelingMexico: COFEPRIS Publishes Self-Verification Guide for Inspection and Traceability of Health Supplies – Drugs
COFEPRIS issues a self-verification guide to support compliance with sanitary inspection and traceability requirements for medicinal and herbal products, providing operational criteria to strengthen internal controls and regulatory readiness.
COFEPRIS | Pharmaceuticals | Regulatory AffairsBrazil: ANVISA approves new regulatory framework for herbal medicines
ANVISA approved a new regulatory framework simplifying registration and expanding the use of biodiversity in herbal medicines in Brazil.
ANVISA | Pharmaceuticals | Regulatory AffairsMexico: COFEPRIS Publishes Catalogue of Criteria and Requirements for Submitting Drug Samples for Analysis
COFEPRIS issued a guidance document detailing the criteria, documentation, and analytical requirements for submitting pharmaceutical, biological, vaccine and API samples for laboratory analysis at CCAYAC-accredited facilities.
COFEPRIS | Pharmaceuticals | Regulatory Affairs
Consult
